Search our Database of Scientific Publications and Authors

I’m looking for a

    3249 results match your criteria Prolactinoma

    1 OF 65

    Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma.
    Indian J Endocrinol Metab 2017 Jan-Feb;21(1):154-159
    Department of Endocrinology, Seth G S Medical College and KEM Hospital, Mumbai, Maharashtra, India.
    Background: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear.

    Objective: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking cabergoline for the treatment of prolactinoma and to explore any associations with the cumulative dose of drug used.

    Design: A cross-sectional echocardiographic study was performed in patients who were receiving cabergoline therapy for prolactinoma. Read More

    Cluster headache and macroprolactinoma: Case report of a rare, but potential important causality.
    J Clin Neurosci 2017 Feb 10. Epub 2017 Feb 10.
    Department of Endocrinology, Universtiy Hospital Basel, University of Basel, Basel, Switzerland. Electronic address:
    While headache is not an uncommon symptom in patients suffering from pituitary adenomas, cluster headache (CH) has rarely been reported in such cases. Headache associated with hyperprolactinemia has been reported to be responsive to dopamine agonists (DA agonists) in many patients. We report on a patient with refractory CH secondary to a macroprolactinoma who showed immediate and permanent clinical and radiologic recovery following medical treatment with DA agonists. Read More

    Giant Prolactinoma Presenting As a Base of Skull Tumor With Nasopharyngeal Extension: A Potential Diagnostic Pitfall in Neuroendocrine Lesions of the Base of Skull.
    Head Neck Pathol 2017 Feb 14. Epub 2017 Feb 14.
    Department of Pathology, University Health Network, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada.
    Pituitary adenomas presenting in uncommon anatomical locations are commonly misdiagnosed. Dramatic clinical presentation with hemorrhage and infarction, along with a lack of endocrine symptoms may further confound the diagnosis in some patients as illustrated in one of our two previously reported cases of non-small cell neuroendocrine carcinoma of the sinonasal tract and nasopharynx. This report presents the clinical progress of case number 2, which has a revised diagnosis of giant lactotroph pituitary adenoma. Read More

    Global expression profile of tumor stem-like cells isolated from MMQ rat prolactinoma cell.
    Cancer Cell Int 2017 31;17:15. Epub 2017 Jan 31.
    0000 0004 0369 153Xgrid.24696.3fBeijing Neurosurgical Institute, Capital Medical University, Beijing, 100050 China ; 0000 0004 0369 153Xgrid.24696.3fDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050 China ; Beijing Institute for Brain Disorders Brain Tumor Center, Beijing, 100050 China ; China National Clinical Research Center for Neurological Diseases, Beijing, 100050 China.
    Background: Cancer stem cells (CSCs), which have been isolated from various malignancies, were closely correlated with the occurrence, progression, metastasis and recurrence of the malignant cancer. Little is known about the tumor stem-like cells (TSLCs) isolated from benign tumors. Here we want to explore the global expression profile of RNA of tumor stem-like cells isolated from MMQ rat prolactinoma cells. Read More

    An Economic Analysis of Bromocriptine Versus Trans-Sphenoidal Surgery for the Treatment of Prolactinoma.
    J Craniofac Surg 2017 Jan 31. Epub 2017 Jan 31.
    *Key Laboratory of Endocrinology, Ministry of Health; Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences †Department of Clinical Medicine, Peking Union Medical College ‡Department of National Health Accounts and Policy Studies, China National Health Development Research Center, Beijing, China.
    Prolactinomas account for ∼40% of all pituitary adenomas and are important causes of infertility and gonadal dysfunction. In general, most prolactinomas are treated medically with dopaminergic agonists, while surgery is reserved for patients intolerant or nonresponsive to these medications. The aim of this study was to carry out a comparative analysis of the cost-effectiveness of medical therapy with bromocriptine and surgical therapy with trans-sphenoidal surgery. Read More

    A combined opiate agonist and antagonist treatment reduces prolactin secreting pituitary tumor growth.
    J Cell Commun Signal 2017 Jan 31. Epub 2017 Jan 31.
    Endocrine Program, Department of Animal Sciences, Rutgers, The State University of New Jersey, 67 Poultry Farm Lane, New Brunswick, NJ, 08901, USA.
    Prolactin secreting pituitary adenomas (prolactinomas) is the most common pituitary tumors in humans. Animal studies have identified aggressive prolactinoma development in fetal alcohol exposed rats. We have recently identified a combination treatment of a μ opioid receptor antagonist naltrexone and a δ opioid receptor agonist D-Ala2-,N-Me-Phe4,Gly-ol Enkephalin (DPDPE) increases innate immune function. Read More

    Bromocriptine induces autophagy-dependent cell death in pituitary adenomas.
    World Neurosurg 2017 Jan 27. Epub 2017 Jan 27.
    Departments of Neurosugery, Binzhou Medical University Hospital, Binzhou, China.
    Background: Bromocriptine(BRC) is effective in patients with prolactinoma. However, the cytotoxic mechanism of BRC remains unknown.

    Methods: Slices for immunohistochemical pathology were randomly selected from 37 paraffin-embedded prolactinoma tissue sections. Read More

    Endovascular therapy using flow diversion for giant internal carotid artery pseudoaneurysm arising in the setting of an invasive pituitary macroadenoma.
    Proc (Bayl Univ Med Cent) 2017 Jan;30(1):47-49
    Departments of Diagnostic and Neurointerventional Radiology, Baylor University Medical Center at Dallas. Dr. Saad is now with Stanford University, and Dr. Marashi is now with University of Utah, Salt Lake City.
    This report illustrates the unusual occurrence of a pseudoaneurysm arising in the setting of a skull base mass and describes the first reported use of endovascular flow diversion therapy in such a setting. A 63-year-old man with occasional headaches during the preceding month presented with the acute onset of severe left retroorbital headache and oculomotor nerve palsy. Computed tomography (CT) and CT angiogram revealed a destructive skull base mass with an associated giant probable pseudoaneurysm of the cavernous segment of the left internal carotid artery. Read More

    Identification of M2 macrophages in anterior pituitary glands of normal rats and rats with estrogen-induced prolactinoma.
    Cell Tissue Res 2017 Jan 24. Epub 2017 Jan 24.
    Jichi Medical University, Tochigi, Japan.
    Macrophages are present throughout the anterior pituitary gland. However, the features and function of macrophages in the gland are poorly understood. Recent studies have indicated that there are two main macrophage classes: M1 (classically activated) and M2 (alternatively activated). Read More

    Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
    Clin Neurol Neurosurg 2017 Feb 14;153:102-106. Epub 2016 Dec 14.
    The First Affiliated Hospital of BengBu Medical College, Department of Neurosurgery, China. Electronic address:
    Objective: Prolactinomas are the most common functional hormone-producing pituitary lesions, accounting for 30-40% of all pituitary tumors, while in autopsy series their incidence reaches 50%. However, patients with prolactinoma had a higher recurrence percentage and rate than patients with acromegaly or Cushing's disease. Furthermore, prolactinomas have the highest rate of recurrence post-surgery as compared with other pituitary adenomas. Read More

    The birth and rise of a craniopharyngioma: the radiological evolution of an incidental craniopharyngioma detected on serial MRI during medical treatment of a macroprolactinoma.
    Clin Case Rep 2017 Jan 20;5(1):14-17. Epub 2016 Nov 20.
    Radiology Department of Medical Sciences University of Cagliari Cagliari Italy.
    This case demonstrates the rare coexistence of a prolactinoma with craniopharyngioma and documents its radiological growth. This case suggests that patients with pituitary neoplasms should be followed closely and although prolactinomas can often be managed medically, a coexistent other lesion may require surgery for histological assessment and to reduce mass effect. Read More

    Sex differences in the development of prolactinoma in mice overexpressing hCGβ: role of TGFβ1.
    J Endocrinol 2017 Mar 17;232(3):535-546. Epub 2017 Jan 17.
    Instituto de Biología y Medicina ExperimentalConsejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
    Female transgenic mice that overexpress the human chorionic gonadotrophin β subunit (hCGβ+) develop prolactinomas, whereas hCGβ+ males do not. The high levels of circulating hCG induce massive luteinization in the ovary of hCGβ+ females, and progesterone becomes the primary steroid hormone produced, but estradiol remains at physiological level. The involvement of high levels of progesterone in lactotroph proliferation is not clearly understood; hence, the pathogenesis of prolactinomas in hCGβ+ females remains unclear. Read More

    Delayed CSF Rhinorrhea after Gamma Knife Radiosurgery with or without Preceding Transsphenoidal Resection for Pituitary Pathology.
    World Neurosurg 2017 Jan 9. Epub 2017 Jan 9.
    Department of Neurologic Surgery, Mayo Clinic, Rochester MN; Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester MN. Electronic address:
    Background: Skull base cerebrospinal fluid (CSF) leak after gamma knife radiosurgery (GKRS) is a very rare complication. In patients who were treated with both GKRS and transsphenoidal resection (TSR) for pituitary lesions, early CSF leak occurs at a comparable rate to the general TSR population (4%). Delayed CSF leak occurring more than a year after TSR, GKRS, or dual therapy, is exceedingly rare. Read More

    Surgical treatment for male prolactinoma: A retrospective study of 184 cases.
    Medicine (Baltimore) 2017 Jan;96(2):e5833
    Department of Neurosurgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Science, Beijing, China.
    A total of 184 cases of surgically treated male prolactinoma were analyzed retrospectively to summarize the outcome of this surgical intervention. We analyzed the general characteristics, clinical manifestations, hormone levels, imaging features, preoperative treatments, surgical outcomes, pathology results, and follow-up records for all included patients. The most common clinical manifestations included sexual dysfunction (47. Read More

    Transdifferentiation of Neuroendocrine Cells: Gangliocytoma Associated With Two Pituitary Adenomas of Different Lineage in MEN1.
    Am J Surg Pathol 2017 Jan 10. Epub 2017 Jan 10.
    Departments of *Endocrinology †Radiology ‡Neurosurgery, Pitié Salpêtrière-Charles Foix Hospital §Department of Neuropathology Raymond-Escourolle, Pitié Salpêtrière-Charles Foix Hospital, INSERM U1127, CNRS UMR 7225, UPMC-Sorbonne University, Brain and Spine Institute ††INSERM U1016, CNRS UMR8104, Paris Descartes University, Cochin Institute, Paris ∥Endocrinology Federation, GH East, Civil Hospital of Lyon, Bron Cedex ¶INSERM U1028, CNRS UMR5292, Lyon 1 University, Neuroscience Center, Lyon **Department of Pathological Cytology and Anatomy, Foch Hospital, Suresnes, France #Department of Endocrinology, CHU de Liège, University of Liège, Liège, Belgium.
    Gangliocytomas are rare and benign neuronal cell tumors, mostly found in the hypothalamic and sellar regions. Their histogenesis is still the subject of discussions. Herein we present a unique case of a pituitary gangliocytoma associated with a prolactinoma and a corticotroph adenoma in a patient affected by MEN1. Read More

    MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment.
    Eur J Endocrinol 2017 Mar 10;176(3):323-328. Epub 2017 Jan 10.
    Aix Marseille UniversityAssistance Publique Hopitaux de Marseille, La Conception Hospital, Marseille, France
    Objective: Both antitumor and antisecretory efficacies of dopamine agonists (DA) make them the first-line treatment of macroprolactinomas. However, there is no guideline for MRI follow-up once prolactin is controlled. The aim of our study was to determine whether a regular MRI follow-up was necessary in patients with long-term normal prolactin levels under DA. Read More

    ESR1 and its antagonist fulvestrant in pituitary adenomas.
    Mol Cell Endocrinol 2017 Mar 31;443:32-41. Epub 2016 Dec 31.
    Key Laboratory of Central Nervous System Injury Research, Center of Brain Tumor of Beijing Institute for Brain Disorders, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China. Electronic address:
    Estrogen has a key role in the pathogenesis of pituitary adenomas (PAs). The study was to evaluate the estrogen receptor alpha (ESR1) level in 289 PAs cases, its association with clinicopathologic features and serving as a target of cancer treatment. In this study, the ESR1 level was evaluated by tissue microarray (TMA). Read More

    Differentiated thyroid cancer in patients with prolactinoma.
    Turk J Med Sci 2016 Nov 17;46(5):1360-1365. Epub 2016 Nov 17.
    Department of Endocrinology and Metabolism, Faculty of Medicine, Yıldırım Beyazıt University, Ankara, Turkey.
    Background/aim: Increasing evidence is available about the role of prolactin in the development of various cancers. The purpose of this study is to evaluate the frequency of thyroid cancer in patients with prolactinoma followed at a single site.

    Materials And Methods: The medical records of 182 patients diagnosed with prolactinoma were reviewed retrospectively. Read More

    Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
    Gynecol Endocrinol 2016 Dec 2:1-4. Epub 2016 Dec 2.
    a Department of Endocrinology , Post Graduate Institute of Medical education and Research (PGIMER) , Chandigarh, 160012 , India.
    Hyperprolactinemia and prolactinomas cause infertility in significant number of women. But, pregnancy may lead to post-partum remission of hyperprolactinemia. The data on pregnancy and tumor outcome in women with macroprolactinoma conceiving on Cabergoline (CAB) therapy is increasing but still less than with Bromocriptine. Read More

    Interactions between prolactin and kisspeptin to control reproduction.
    Arch Endocrinol Metab 2016 Nov-Dec;60(6):587-595. Epub 2016 Nov 24.
    Departamento de Anatomia, Instituto de Ciências Biomédicas, USP, São Paulo, SP, Brasil.
    Prolactin is best known for its effects of stimulating mammary gland development and lactogenesis. However, prolactin is a pleiotropic hormone that is able to affect several physiological functions, including fertility. Prolactin receptors (PRLRs) are widely expressed in several tissues, including several brain regions and reproductive tract organs. Read More

    Prolactinoma and pregnancy - a series of cases including pituitary apoplexy.
    J Obstet Gynaecol 2016 Nov 21:1-4. Epub 2016 Nov 21.
    a Centro Hospitalar do Porto - Centro Materno Infantil do Norte , Porto , Portugal.
    The objective of this article is to evaluate the impact of pregnancy in women with prolactinoma, the possible consequences of therapy maintenance/discontinuation during pregnancy and to assess the type of delivery and maternal-foetal obstetrical outcome. A retrospective study of all pregnant women with prolactinoma in our Centre between 2006 and 2014 was made. We had 35 cases of pregnant women with prolactinoma, two of which had an episode of pituitary apoplexy during the second trimester. Read More

    A macroprolactinoma becoming resistant to cabergoline and developing atypical pathology.
    Endocrinol Diabetes Metab Case Rep 2016 18;2016. Epub 2016 Oct 18.
    Department of Endocrinology , Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford , UK.
    : Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40-60% of all pituitary adenomas, with dopamine agonists representing the first-line treatment and surgery/radiotherapy reserved for drug intolerance/resistance or in neuro-ophthalmological emergencies. Read More

    Late presentation of acromegaly in medically controlled prolactinoma patients.
    Endocrinol Diabetes Metab Case Rep 2016 17;2016. Epub 2016 Oct 17.
    Department of Endocrinology , Diabetes and Metabolism.
    : Co-secretion of growth hormone (GH) and prolactin (PRL) from a single pituitary adenoma is common. In fact, up to 25% of patients with acromegaly may have PRL co-secretion. The prevalence of acromegaly among patients with a newly diagnosed prolactinoma is unknown. Read More


    SERUM LEVELS OF FİBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERİN AND RECEPTOR ACTİVATOR OF NUCLEAR FACTOR KAPPA B LİGAND (RANKL) İN PATİENTS WİH PROLACTİNOMA.
    Endocr Pract 2016 Nov 16. Epub 2016 Nov 16.
    From: 1Diskapi Training and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey.
    Purpose: The aim of this study to was to evaluate the effect of fibroblast growth factor-23 (FGF-23), osteoprotegerin (OPG), receptor activator nuclear kB ligand (RANKL), and vitamin D hormones on bone loss in patients with hyperprolactinemia due to the pituitary prolactinoma.

    Methods: 46 premenopausal female patients with prolactinoma and age and sex matched healthy controls (Group 3, n=20) were recruited to this cross sectional study. Prolactinoma patients were divided into two groups as patients newly diagnosed (Group 1, n=26), and under cabergoline treatment (Group 2, n=20). Read More

    Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
    Pituitary 2016 Nov 15. Epub 2016 Nov 15.
    Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clínicas & Laboratory of Cellular and Molecular Endocrinology LIM-25, University of São Paulo Medical School, São Paulo, Brazil.
    Background: About 80% of prolactinomas respond to dopamine agonists (DA) with hormonal normalization and tumor shrinkage. Mechanisms of DA resistance include reduction of dopamine receptor subtype 2 (DRD2) expression, short and long isoform ratio and post-receptor mechanisms. It was suggested that polymorphisms in the gene encoding dopamine receptor subtype 2 gene (DRD2) could be associated with variable effectiveness of cabergoline (CAB). Read More

    A novel truncating AIP mutation, p.W279*, in a familial isolated pituitary adenoma (FIPA) kindred.
    Hormones (Athens) 2016 07;15(3):441-444
    Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, 20892, USA.
    Familial isolated pituitary adenomas (FIPA) constitute 2-3% of pituitary tumours. AIP is the most commonly mutated gene in FIPA. We herein report a novel germline mutation of the AIP gene in a family with FIPA. Read More

    Effect of bisphenol a on occurrence and progression of prolactinoma and its underlying mechanisms.
    Am J Transl Res 2016 15;8(10):4195-4204. Epub 2016 Oct 15.
    Department of Endocrinology, Qilu Hospital, Shandong University Jinan 250012, China.
    Objective: To investigate the effects of Bisphenol A (BPA) on prolactin (PRL) release, pituitary cell proliferation, prolactinoma formation in estrogen-sensitive Fischer 344 (F344) rats.

    Materials And Methods: Four-week-old female F344 rats were orally administered with different concentrations of BPA or intraperitoneal injection of estradiol benzoate (estradiolbenzoate, E2) for 12 weeks. Bodyweight, blood RPL level and pituitary weights were observed and recorded. Read More

    Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide.
    J Pediatr Endocrinol Metab 2016 Dec;29(12):1413-1415
    Prolactinomas are a rare subset of brain tumors in pediatrics. We report a child with a prolactin secreting macroadenoma which was refractory to initial treatment with a dopamine antagonist. Given the location of her tumor she was ineligible for surgical resection. Read More

    Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
    Pituitary 2016 Oct 25. Epub 2016 Oct 25.
    Saint-Joseph University, Beirut, Lebanon.
    Background: Prolactinomas are the commonest functional tumors of the pituitary gland. There are still controversies regarding medical therapy in specific clinical situations. Patients may be managed by different specialists in the Middle East and North Africa (MENA) region and no data exist on patterns of clinical management. Read More

    Pituitary tumors in MEN1: do not be misled by borderline elevated prolactin levels.
    Pituitary 2016 Dec;19(6):601-604
    Division of Endocrinology Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530, Chicago, IL, 60611, USA.
    Purpose: The objective of this case report is to demonstrate that the simple expedient of measuring periodic prolactin levels in patients with MEN1 who have modest hyperprolactinemia and normal pituitary MRI scans is insufficient to monitor for the development of pituitary adenomas.

    Methods: Review of relevant literature and chart review.

    Results: A 25 year old man with known MEN1 manifested by hyperparathyroidism and a gastrin-producing neuroendocrine tumor was found to have a prolactin [PRL] level of 20. Read More

    Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health.
    World Neurosurg 2017 Jan 20;97:595-602. Epub 2016 Oct 20.
    Department of Endocrinology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address:
    Objective: In men with prolactinomas, impaired bone density is the principle consequence of hyperprolactinemia-induced hypogonadism. Although dopamine agonists (DAs) are the first-line approach in prolactinomas, surgery can be considered in selected cases. In this study, we aimed to investigate the long-term control of hyperprolactinemia, hypogonadism, and bone health comparing primary medical and surgical therapy in men who had not had prior DA treatment. Read More

    Significance of surgical management for cystic prolactinoma.
    Pituitary 2016 Oct 18. Epub 2016 Oct 18.
    Department of Neurosurgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
    Purpose: It is generally accepted that dopamine agonists (DA) represent the first-line treatment for most patients with prolactinoma, and patients become candidates for surgical intervention when DA is contraindicated. Surgical indication for cystic prolactinoma remains controversial. This study was performed to investigate the significance of surgery for cystic prolactinoma. Read More

    Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience.
    Endocrine 2016 Oct 26;54(1):191-197. Epub 2016 Jul 26.
    Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
    Our objective was to compare prevalence and rates of recovery of hypothalamic-pituitary-adrenal axis dysfunction in prolactinoma patients before and after dopamine agonist therapy with nonfunctioning pituitary adenoma patients pre-transsphenoidal and post-transsphenoidal surgery. We retrospectively compared hypothalamic-pituitary-adrenal axis function in patients with prolactinomas naïve to dopamine agonist therapy with a cohort of nonfunctioning pituitary adenoma patients matched for gender and tumor size by classification (n = 57; 30 male/27 female; 27 microadenoma/30 macroadenoma). Patients with <52 weeks follow up, previous medical therapy, surgery, or radiation therapy were excluded. Read More

    The risks of overlooking the diagnosis of secreting pituitary adenomas.
    Orphanet J Rare Dis 2016 Oct 6;11(1):135. Epub 2016 Oct 6.
    Hôpital de la Conception 147, Boulevard Baille, 13285, Marseille Cedex 05, France.
    Secreting pituitary adenomas that cause acromegaly and Cushing's disease, as well as prolactinomas and thyrotroph adenomas, are uncommon, usually benign, slow-growing tumours. The rarity of these conditions means that their diagnosis is not familiar to most non-specialist physicians. Consequently, pituitary adenomas may be overlooked and remain untreated, and affected individuals may develop serious comorbidities that reduce their quality of life and life expectancy. Read More

    The epidemiology of pituitary adenomas in a community-based hospital: a retrospective single center study in Saudi Arabia.
    Ann Saudi Med 2016 Sep-Oct;36(5):341-345
    Khalid S. Aljabri, MD, FRCPC, Department of Endocrinology,, King Fahad Armed Forces Hospital,, PO Box 6572, Jeddah 24361,, Saudi Arabia, T: 966555544919, F: 966-22-576-0665, ORCID: http://orcid.org/000-0001-5831-5935.
    Background: Data on pituitary adenoma (PA) prevalence in Saudi Arabia are scarce.

    Objective: To estimate the epidemiology of PA in a well-defined population.

    Design: Retrospective analysis. Read More

    Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
    Endocrine 2017 Jan 5;55(1):239-245. Epub 2016 Oct 5.
    Department of Endocrinology, Center Hospitalier Universitaire de Liège, University of Liège, Domaine Universitaire du Sart-Tilman, Liège, 4000, Belgium.
    Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. Read More

    Long-term outcome of multimodal therapy for giant prolactinomas.
    Endocrine 2017 Jan 4;55(1):231-238. Epub 2016 Oct 4.
    Endocrinology Division, Complejo Hospitalario Universitario de Santiago de Compostela (CHUS)-SERGAS, Santiago de Compostela, 15706, Spain.
    Giant prolactinomas are rare tumors characterized by their large size, compressive symptoms, and extremely high prolactin secretion. The aim of this study is to describe our experience with a series of 16 giant prolactinomas cases in terms of clinical presentation, therapeutic decisions, and final outcomes. Retrospective analysis of adult patients diagnosed with giant prolactinomas at the endocrine departments of three university tertiary hospitals. Read More

    Cabergoline or bromocriptine for prolactinoma?
    Medwave 2016 Sep 15;16(Suppl3):e6545. Epub 2016 Sep 15.
    Departamento de Medicina Interna, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Proyecto Epistemonikos, Santiago, Chile; Programa de Salud Basada en Evidencia, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; GRADE working group; The Cochrane Collaboration.
    Cabergoline and bromocriptine are among the most commonly used drugs to treat prolactinoma. Cabergoline is a long-acting dopamine receptor agonist which might offer advantages over bromocriptine. However, it is not clear if this translates into clinical benefits. Read More

    10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Endocrine 2017 Jan 29;55(1):223-230. Epub 2016 Sep 29.
    Endocrinology Diabetes and Metabolism, Bern University Hospital, University of Bern, Bern, Switzerland.
    While dopamine-agonists are the first-line approach in treating prolactinomas, surgery can be considered in selected cases besides non-responders or patients with dopamine-agonist intolerance. The aim of the present study was to compare the long-term outcome in women with prolactinomas treated primarily either surgically or medically who had not had prior dopamine-agonist treatment. Retrospective case-note study of all consecutive women with prolactinomas primarily managed with medical therapy or surgery in a tertiary referral centre. Read More

    SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Endocr Pract 2017 Jan 28;23(1):37-45. Epub 2016 Sep 28.
    Objective: Prolactinomas are primarily treated with medical therapy. Given the efficacy of dopamine agonists (DAs), surgery has remained a second-line treatment option. Despite medical therapy, some tumors display resistance and/or patients maybe intolerant of DA and require alternative treatment options. Read More

    Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression.
    World Neurosurg 2017 Jan 23;97:2-7. Epub 2016 Sep 23.
    Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
    Background: Primary lactotroph disinhibition, or stalk effect, occurs when mechanical compression of the pituitary stalk disrupts the tonic inhibition by dopamine released by the hypothalamus. The resolution of pituitary stalk effect-related hyperprolactinemia postoperatively has not been studied in a large cohort of patients. We performed a retrospective review to investigate the time course of recovery of lactotroph disinhibition after transsphenoidal surgery. Read More

    [Hyperprolactinemia: unusual association between peripheral hypothyroidism and microprolactinoma].
    Pan Afr Med J 2016 10;24:41. Epub 2016 May 10.
    Service d'Endocrinologie Diabétologie et Maladies Métaboliques, Hopital Arrazi, CHU Mohamed VI, Faculté de Médecine et de Pharmacie, Université Cadi Ayad, Marrakech, Maroc.
    We report a rare case of hyperprolactinemia revealing the association between peripheral hypothyroidism and prolactin pituitary macroadenomas. The patient was a 43-year old woman, presenting with spontaneous bilateral galactorrhea over a period of 1 year. Hyperprolactinemia was confirmed and etiologic investigation revealed peripheral hypothyroidism secondary to autoimmune thyroiditis. Read More

    Long-term outcome of macroprolactinomas.
    Ann Endocrinol (Paris) 2016 Dec 15;77(6):641-648. Epub 2016 Sep 15.
    Service de médecine interne, nutrition et endocrinologie, hôpital de Hautepierre, University Hospital of Strasbourg, 1, avenue Molière, 67098 Strasbourg cedex, France; Faculty of Medicine, University of Strasbourg, 4, rue Kirschleger, 67000 Strasbourg, France. Electronic address:
    Objective: Management of macroprolactinomas has dramatically changed in recent decades, from surgical to medical treatment as first-line therapy, with the development of dopamine agonists (DA). But few data exist on the long-term outcome of these patients.

    Patients And Methods: Retrospective descriptive multicenter study of patients with macroprolactinoma followed for at least 5 years between 1973 and 2008 at the University Hospitals of Strasbourg and Marseille. Read More

    Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
    Endocrine 2017 Feb 6;55(2):618-624. Epub 2016 Sep 6.
    School of Medicine, University of Adelaide, Adelaide, SA, Australia.
    Dopamine agonists are the first line of therapy for prolactinomas, with high rates of biochemical control and tumour shrinkage. Toxicity is considered to be low and manageable by switching of agents and dose reduction. Dopamine agonist-induced impulse control disorders are well described in the neurology setting, but further data are required regarding this toxicity in prolactinoma patients. Read More

    Predictive Factor of Surgical Efficacy in Male Patients with Prolactinoma.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2016 Aug;38(4):383-7
    Department of Neurosurgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
    Objective To analyze the predictive factor of surgical efficacy in male patients with prolactinoma. Method The clinical data of 184 male patients with prolactinoma who had undergone surgery were retrospectively analyzed.Results Before the surgery,the serum prolactin level from 150 to 204 952 ng/ml,the tumors sized 6 to 70 mm. Read More

    Concomitant existence of pheochromocytoma in a patient with multiple endocrine neoplasia type 1.
    Surg Case Rep 2016 Dec 30;2(1):84. Epub 2016 Aug 30.
    Department of Organ Regulatory Surgery, Fukushima Medical University, Fukushima, Japan.
    Background: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal-dominant inherited disorder that is classically characterized by the presence of neoplastic lesions of the parathyroid glands, the anterior pituitary gland, and the pancreas. However, MEN1 with concomitant pheochromocytoma is extremely rare.

    Case Report: We report a case of MEN1 concomitant with pheochromocytoma. Read More

    Management of hormone-secreting pituitary adenomas.
    Neuro Oncol 2016 Aug 19. Epub 2016 Aug 19.
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland (G.U.M., R.R.L.); Department of Neurological Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio (R.R.L.).
    Pituitary adenomas are one of the most common primary central nervous system tumors and have an estimated prevalence of 17%. Approximately half of pituitary adenomas secrete distinct pituitary hormones (most often prolactin, growth hormone, or adrenocorticotropic hormone). While these tumors are histologically benign, they have potent endocrine effects that lead to significant morbidity and shortened lifespan. Read More

    1 OF 65